DuraHeart™ magnetically levitated centrifugal left ventricular assist system for advanced heart failure patients

  • Morshuis M
  • Schoenbrodt M
  • Nojiri C
 et al. 
  • 9


    Mendeley users who have this article in their library.
  • 30


    Citations of this article.


The implantable left ventricular assist system (LVAS) using pulsatile pump technology has become an established therapeutic option for advanced heart failure patients. However, there have been technological limitations in some older designs, including a high incidence of infection and mechanical failures associated with moving parts, and the large size of both implantable pump and percutaneous cable. A smaller rotary blood pump emerged as a possible alternative to a large pulsatile pump to overcome some of these limitations. The technological advancement that defines the third-generation LVAS was the elimination of all mechanical contacts between the impeller and the drive mechanism. The DuraHeart LVAS is the world's first third-generation implantable LVAS to obtain market approval (CE-mark), which combines a centrifugal pump and active magnetic levitation. The initial clinical experience with the DuraHeart LVAS in Europe demonstrated that it provided significantly improved survival (85% at 6 months and 79% at 1 year), reduced adverse event rates and long-term device reliability (freedom from device replacement at 2 years: 96 +/- 3%) over pulsatile LVAS.

Author-supplied keywords

  • Heart failure
  • Heart transplantation
  • Left ventricular assist device

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Michiel Morshuis

  • Michael Schoenbrodt

  • Chisato Nojiri

  • Daniela Roefe

  • Sebastian Schulte-Eistrup

  • Jochen Boergermann

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free